Skip to main content
2026 Prospectus
CLOVES Syndrome Awareness Day 2026 executive healthcare observance hero.

· Executive Brief

CLOVES Syndrome Awareness Day 2026

Use the observance to review how people find information, enter the right route, and remain connected through follow-through.

Greg Wahlstrom in his office at The Healthcare Executive
Written byMBAHCMPresident and Chief Executive Officer, The Healthcare ExecutiveOctober 2026 30 min read

Leadership signal

Recognition becomes useful when leaders inspect the real route.

The strongest use of the observance is operational. Map where questions enter, how requests move, when ownership changes, and how unresolved work becomes visible. The goal is not to make a clinical claim. It is to make the organization’s response easier to understand and manage.

Start by distinguishing what is known from what the organization still needs to learn. A campaign plan, communication volume, or meeting count does not establish that a route is usable. Leaders need direct listening, clear ownership, locally defined measures, and a method for keeping exceptions visible.

Executive opening

A rare diagnosis tests whether the system can coordinate itself

CLOVES Syndrome Awareness Day draws attention to a rare condition that combines tissue overgrowth with complex vascular malformations. For health system leaders, the operating question is simple to state and hard to answer. Can a child with a rare, multisystem diagnosis reach coordinated expertise without the family becoming the coordinator?

Conditions in the PIK3CA-related overgrowth spectrum arise from somatic gain-of-function variants in the PIK3CA gene.[3] In a United States study of patients and caregivers, these conditions had a negative effect on quality of life, most often through pain and loss of physical functioning.[3] Those effects persisted across the entire study period of up to 12 months.[3]

Care for these children rarely sits in one department. Dermatology, interventional radiology, surgery, hematology, genetics, orthopedics and rehabilitation may each hold part of the plan. A ten-year review of one pediatric vascular anomalies committee found that 53.3% of 180 children required therapeutic intervention, and 85% had a favorable course.[1] Those results are reported for a team that meets, decides and follows up, not for any single specialist.

Treatment is also changing. A recent review describes vascular anomaly care shifting toward genotype-informed and pathway-directed medical therapy alongside embolization and other procedures.[7] That shift adds genetic testing, specialty pharmacy, laboratory monitoring and years of follow-up to an already crowded route. Families who live far from a specialty center face the longest and most fragile version of that route.

The sections below summarize peer-reviewed evidence on burden, coordination, access to targeted therapy, transitions, family experience, workforce and measurement. They sit beside the executive guidance already on this page and give boards and operating leaders a shared factual base for deciding where to act first.

Current evidence

What the research says about complexity, burden and coordinated review

Rare vascular anomalies with overgrowth are clinically and genetically diverse, which makes a single referral rule hard to write. A retrospective study across five Italian tertiary centers enrolled 41 children with a vascular malformation, regional overgrowth and a confirmed variant outside PIK3CA.[4] Variants appeared in seven different genes, somatic variants accounted for 65.9% of cases, and functional limitations affected 43.9% of patients.[4] The authors found marked phenotypic overlap across genes, which made classification by appearance alone unreliable.[4]

Systemic effects can stay hidden until someone looks for them. In a single-center review of 437 patients treated for peripheral arteriovenous malformations between 2000 and 2022, 24.7% had cardiomegaly on chest radiographs.[11] Lesion type, a diameter over 10 cm and bone involvement were significant risk factors.[11] In a cohort of 27 patients with KRAS-related Parkes Weber syndrome of the lower limbs, all had a limb length difference over 1 cm, and 70% had chyle leakage.[9]

Committee-based review is one documented way to manage this complexity. A multidisciplinary vascular anomalies committee reviewed 180 children under 14 years between January 2014 and January 2024.[1] Its initial recommendations were further testing in 32.2% of cases, treatment initiation in 27.2% and conservative management in 25.6%.[1] Favorable evolution was observed in 85%, including complete resolution in 22%, clinical improvement in 33% and stabilization in 30%.[1] The study was descriptive and had no comparison group, so it shows what coordinated review looks like rather than showing that it outperforms other models.

Long-term experience shows the toll of advanced disease. From 1995 to 2023 at one center, 150 patients with hand arteriovenous malformations received multidisciplinary care.[12] Sclerotherapy-related adverse events occurred in 123 of 320 sessions (39%), and 15 patients (15%) treated with sclerotherapy eventually underwent amputation.[12] A smaller series found that 6 of 16 patients with Parkes Weber syndrome had clinical and imaging features suggesting lymphatic malformation (37.5%).[15] These figures describe a population that needs durable, expert and coordinated follow-up rather than episodic referral.

For executives, the practical reading of this evidence is about variety and visibility. Patients with similar appearances may carry different variants, and serious systemic findings may surface only through deliberate assessment. A pathway that relies on each specialist to notice what falls outside their own field will miss some of that burden. A shared review, a common record of imaging and genetics and an agreed set of baseline assessments give the whole team the same picture of each patient.

Figure 1

Complex vascular anomalies carry heavy burden and depend on scarce coordinated expertise

Complex vascular anomalies carry heavy burden and depend on scarce coordinated expertisePercent of each study population with the reported finding, as stated in each abstract. Values are copied from the cited studies [1], [4], [11], [12], [14]; none is estimated.0%25%50%75%100%Children with favorable evolution aftercommittee reviewChildren with favorable evolution after committee review: 85% (source [1])85%[1]Children with functional limitationsChildren with functional limitations: 43.9% (source [4])43.9%[4]Sclerotherapy sessions with adverseeventsSclerotherapy sessions with adverse events: 39% (source [12])39%[12]Patients with cardiomegalyPatients with cardiomegaly: 24.7% (source [11])24.7%[11]Residents trained whereinterdisciplinary vascular anomalyResidents trained where interdisciplinary vascular anomaly clinics exist: 23.1% (source [14])23.1%[14]Source [1]Source [4]Source [12]Source [11]Source [14]Shade and hatching group bars by study; the studies differ in population and setting, so bars compare only within a shade

Percent of each study population with the reported finding, as stated in each abstract. Values are copied from the cited studies [1], [4], [11], [12], [14]; none is estimated.

Data note. These values come from different studies, populations, settings and denominators, so this is an indirect comparison; the bars show the scale of burden and scarce expertise, not how one finding relates to another.

Limitation. Most sources are retrospective single-center or small multicenter series, and the workforce figure comes from a survey with a 15.5% response rate.

Figure data (5 rows)
Figure 1 data: Complex vascular anomalies carry heavy burden and depend on scarce coordinated expertise
MeasureValuePopulation, setting and year as reportedSource
Children with favorable evolution after committee review85%180 children under 14 years reviewed by one multidisciplinary vascular anomalies committee, January 2014 to January 2024[1]
Children with functional limitations43.9%41 children with non-PIK3CA vascular malformations and overgrowth, five Italian tertiary centers[4]
Sclerotherapy sessions with adverse events39%123 of 320 sessions for hand arteriovenous malformations, single center, 1995 to 2023[12]
Patients with cardiomegaly24.7%108 of 437 patients treated for peripheral arteriovenous malformations, single center, 2000 to 2022[11]
Residents trained where interdisciplinary vascular anomaly clinics exist23.1%Oral and maxillofacial surgery residents completing a U.S. national survey, 2022[14]
A clinic coordinator greets a mother and her ten-year-old daughter and hands them a visit schedule card.
Illustrative image. One pediatric vascular anomalies committee reported favorable evolution in 85% of 180 children it reviewed.[1]

Continuum of care

Continuity across years, specialties and the move to adult care

Vascular anomalies often require longitudinal multidisciplinary care.[7] A recent narrative review notes that many lesions are diffuse, recurrent or syndromic, so procedures alone may give incomplete or temporary control.[7] Medical therapy has the potential to reduce pain, bleeding, coagulopathy, lesion activity and the need for repeated procedures.[7] Each of those goals needs a named owner for indications, monitoring and treatment duration across many years.

The age profile of published cohorts shows why transition planning matters. In a prospective venous malformation series of 33 patients treated from 2019 to 2023, the median age was 20 years, and 17 patients were born with the condition.[10] Reported outcomes were complete regression in 10 patients and partial improvement in 12, while 7 had failure or recurrence.[10] In the overgrowth spectrum study, median patient age was 26 years and median time since diagnosis was 7 years.[3] These conditions outlast any pediatric program.

Families often feel the gaps between settings first. Community caregivers interviewed about children with medical complexity named transition to adult care as one of four main themes.[13] They described serving as advocates, coordinators and primary sources of information about each child’s needs.[13] When a pediatric vascular anomalies team hands off to adult services, someone must carry the history, imaging, genetic results and treatment record, or the family will.

Follow-up must be planned in years, not weeks. In the hand malformation series, amputation after sclerotherapy occurred a mean of 1618 days after treatment, and 36 patients (24%) were followed without any procedure.[12] Surveillance without intervention is still care, and it needs scheduling, imaging and accountable review like any other pathway. Follow-up imaging was also incomplete: in the cardiomegaly study, 84 of 108 affected patients had follow-up chest radiographs.[11]

A practical continuum has three properties. Every patient has a lead clinician and a coordinator who know the full plan. Every planned study, procedure and therapy review has a date and an owner, even when the interval is long. Every transfer between pediatric, adult, community and specialty services is confirmed by the receiving team rather than assumed. Community caregivers suggested that telehealth and mobile health apps could improve care management and quality of life for children with medical complexity.[13]

Figure 3

Why the pathway breaks

Cause-and-effect diagram: Children and adults with complex vascular anomalies and overgrowth do not reach timely coordinated review, targeted therapy and continuous lifelong follow-upUnranked qualitative cause-and-effect diagram for the outcome in the box: Children and adults with complex vascular anomalies and overgrowth do not reach timely coordinated review, targeted therapy and continuous lifelong follow-up Causes are assembled from the cited literature [1], [2], [3], [4], [5], [6], [11], [13], [14]; categories are not weighted and their order carries no meaning.Children and adults withcomplex vascular anomalies andovergrowth do not reach timelycoordinated review, targetedtherapy and continuouslifelong follow-upPeopleProcessTechnologyEnvironmentPolicyMeasurement

People

  • Few clinicians trained in interdisciplinary vascular anomaly care
  • Coordinator and data manager roles unfunded
  • Families and community caregivers carry coordination informally

Process

  • No single entry point to multidisciplinary review
  • Separate specialty visits instead of coordinated days
  • No planned handoff from pediatric to adult services

Technology

  • Registry and clinical data not interoperable
  • Limited remote follow-up options
  • Imaging and genetic results scattered across systems

Environment

  • Long travel distances to specialty centers
  • Disruptions that interrupt in-person care
  • Rural and low-income families with fewer supports

Policy

  • Authorization barriers for genetic testing and targeted therapy
  • Committee time not recognized in productivity models
  • Weak pathway governance and financing

Measurement

  • Family-reported outcomes not collected
  • Follow-up completion across specialties not tracked
  • Results not stratified by payer, language or distance

Unranked qualitative cause-and-effect diagram for the outcome in the box: Children and adults with complex vascular anomalies and overgrowth do not reach timely coordinated review, targeted therapy and continuous lifelong follow-up Causes are assembled from the cited literature [1], [2], [3], [4], [5], [6], [11], [13], [14]; categories are not weighted and their order carries no meaning.

Data note. Qualitative; no frequencies are implied.

Limitation. Causes drawn from published studies may not all apply locally; validate them with frontline teams.

Figure data (6 rows)
Figure 3 data: Why the pathway breaks
CategoryCauses drawn from the cited literature
PeopleFew clinicians trained in interdisciplinary vascular anomaly care; Coordinator and data manager roles unfunded; Families and community caregivers carry coordination informally
ProcessNo single entry point to multidisciplinary review; Separate specialty visits instead of coordinated days; No planned handoff from pediatric to adult services
TechnologyRegistry and clinical data not interoperable; Limited remote follow-up options; Imaging and genetic results scattered across systems
EnvironmentLong travel distances to specialty centers; Disruptions that interrupt in-person care; Rural and low-income families with fewer supports
PolicyAuthorization barriers for genetic testing and targeted therapy; Committee time not recognized in productivity models; Weak pathway governance and financing
MeasurementFamily-reported outcomes not collected; Follow-up completion across specialties not tracked; Results not stratified by payer, language or distance

Access

Access to expertise, targeted therapy and care closer to home

Targeted therapy has changed what access means. Alpelisib recently received approval in the United States for the overgrowth spectrum.[3] Participants receiving it self- and proxy-reported improvements in pain, physical functioning and daily activities.[3] Only 14 participants reported treatment at enrollment, so the study describes lived experience rather than the size of any effect.[3] For a health system, access now includes genetic confirmation, authorization, specialty pharmacy and safety monitoring, not only a clinic slot.

Genetic diagnosis is a gate in that route. Investigators in the multicenter cohort used a 17-gene targeted panel on peripheral blood, buccal swab or affected-tissue biopsy samples.[4] They called for broad panels with tissue-based analysis, systematic parental testing and molecularly driven classification.[4] They also observed clinical improvement with alpelisib in selected patients with TEK variants, supporting pathway-directed thinking beyond the PIK3CA group.[4] Each step needs tissue handling, laboratory partnerships and result follow-up that a referral letter cannot provide.

Distance and disruption are real barriers, and remote supervision is one documented response. A specialized vascular anomalies center in Ukraine evaluated 2,419 children with infantile hemangioma between 2019 and 2024.[5] Because topical therapy could be given at home under remote medical supervision during ongoing military action, all families offered a choice selected that option.[5] Positive outcomes were reported in 98.04% of children who started before age 1 and 69.03% of those who started between ages 1 and 5.[5] The authors concluded that the findings support telemedicine-based treatment when in-person access is limited.[5]

Expertise itself is scarce. In a national survey of oral and maxillofacial surgery residents, only 23.1% trained at facilities with interdisciplinary vascular anomaly clinics.[14] When few clinicians are trained, coordinated single-day visits, shared imaging review and remote follow-up are practical ways to stretch the time of the specialists a system has. Leaders can track travel distance, repeat trips and days from referral to first joint review as signals of access.

Access also has a front door. Families searching for help after a new finding need a published entry point, a person who answers and a first review date. Referring clinicians need simple criteria for when to send a case to the multidisciplinary team. Without those basics, the expertise described in these studies stays available mainly to families who already know how to find it.

Executive guidance · System route

Map the path from first contact to verified follow-through.

Use this route as a discussion framework. Replace each stage with the organization’s approved process, qualified roles, current service capacity, and applicable requirements. Do not infer a clinical protocol from the observance title.

The route at a glance

  1. Listen
  2. Clarify entry
  3. Navigate specialty boundaries
  4. Protect transitions
  5. Verify and learn

Reliability rule: Every stage needs a named owner, an observable status, an approved escalation path, and a defined signal that shows whether responsibility moved or remained unresolved.

  1. Listen

    Gather questions and friction points from people using the route, frontline teams, and community-facing staff. Separate observed barriers from assumptions.

  2. Clarify entry

    Publish a plain-language first step and identify who receives requests through each approved channel.

  3. Navigate specialty boundaries

    Clarify how questions reach the appropriate locally designated resource when knowledge, capacity, or responsibility spans multiple teams or organizations.

  4. Protect transitions

    Use acknowledgment and status visibility when responsibility moves between services, locations, or organizations.

  5. Verify and learn

    Review unresolved work, repeat contacts, and avoidable handoffs. Use the findings to improve the route rather than blame individuals.

Figure 2

The system route as one flow

The system route as one flowThe five stages of the system route described in this brief, drawn as one flow with a learning loop back to the start. The stages are the page’s original executive guidance, not a clinical protocol.ListenClarify entryNavigatespecialtyboundariesProtecttransitionsVerify and learnLearning returns to the start of the route

The five stages of the system route described in this brief, drawn as one flow with a learning loop back to the start. The stages are the page’s original executive guidance, not a clinical protocol.

Data note. Shows sequence and handoffs only; it carries no counts or rates.

Limitation. Local processes may add, merge or reorder stages under organizational policy.

Figure data (5 rows)
Figure 2 data: The system route as one flow
StageWhat the stage requires
ListenGather questions and friction points from people using the route, frontline teams, and community-facing staff. Separate observed barriers from assumptions.
Clarify entryPublish a plain-language first step and identify who receives requests through each approved channel.
Navigate specialty boundariesClarify how questions reach the appropriate locally designated resource when knowledge, capacity, or responsibility spans multiple teams or organizations.
Protect transitionsUse acknowledgment and status visibility when responsibility moves between services, locations, or organizations.
Verify and learnReview unresolved work, repeat contacts, and avoidable handoffs. Use the findings to improve the route rather than blame individuals.

Equity and trust

Equity and trust when expertise is concentrated

Rare disease care concentrates expertise in a few centers, so geography can decide who receives coordinated care. A European consensus study engaged 216 workshop participants from 16 countries to define requirements for rare disease care pathways.[2] Access and equity emerged as one of seven thematic areas, alongside financing, care coordination, digital infrastructure, capacity building and patient empowerment.[2] Eighty-eight participants completed the Delphi survey, and consensus was achieved on all statements in the first round.[2]

Families least able to navigate often rely most on informal helpers. Community caregivers described themselves as facilitators of access to care and often the first point of contact for families.[13] That role was particularly important for families in rural areas, low-income households and non-English-speaking immigrant populations.[13] A health system that does not know these helpers exist cannot support them, share information with them or route families through them reliably.

Trust also depends on whose voices a program hears. The overgrowth spectrum study recruited patients and caregivers through patient advocacy organizations as well as clinical sites.[3] Of its 77 participants, 19 were caregivers, and the group represented 6 syndrome types.[3] Advocacy partnerships can widen who is heard, but leaders should check whether those voices reflect the full population the system serves, including families without an existing specialty connection.

Equity includes accurate diagnosis. When phenotypes overlap across genes, appearance-based classification is unreliable, which is why the authors argue for molecularly driven classification.[4] If testing depends on which specialist a family happens to see first, diagnostic gaps may track insurance, distance and referral patterns. Leaders can stratify testing completion and time to diagnosis by payer, preferred language and travel distance to see whether that is happening in their own population.

Data infrastructure is an equity tool as well. When registry and clinical records cannot be linked, programs struggle to see who is missing from their populations. A French implementation study showed that national registry data can be transformed into a research warehouse when business rules are made explicit and auditable.[6] Programs can apply the same discipline to demographic and access fields, so that gaps by language, payer or region are visible rather than assumed.

Two physicians talk with a mother as her daughter sits on the exam table and a nurse coordinator takes notes.
Illustrative image. A vascular anomalies center supported home treatment under remote supervision when in-person access was limited.[5]

Human infrastructure

The people who hold a vascular anomalies program together

Specialist exposure is thin even in fields that regularly see these patients. A survey sent to 633 oral and maxillofacial surgery residents in the United States drew 98 responses (15.5%), with 91 completed (14.4%).[14] Over half (56%) had no experience with vascular anomaly care teams, and 35.2% lacked specific vascular anomaly education.[14] Although 67% had case exposure, 33% felt unconfident treating head and neck vascular lesions or managing oral health for these patients.[14]

The low response rate limits generalization, but the pattern matters for workforce planning. A vascular anomalies center relies on clinicians across many specialties who must recognize lesions, refer early and contribute to joint plans. The committee, reviewed across a decade of practice, drew on collaborative specialist expertise to reach shared recommendations for 180 children.[1] Protected meeting time, case preparation and follow-up tracking are the hidden labor behind those recommendations, and they rarely appear in productivity models.

Procedural teams also need support for risk communication. A retrospective study of 80 bleomycin electrosclerotherapy procedures in 72 patients described skin hyperpigmentation as a frequent but often underestimated adverse effect.[8] Hyperpigmentation was more frequent after intravenous administration (61.8%) than intralesional administration (41.3%), which the authors linked to higher dosing.[8] They noted that recognizing these factors allows more informed electrode selection and patient counseling.[8]

Coordinators and data staff are part of the clinical workforce in rare disease. Community caregivers identified suggested tools and health IT feature preferences as main themes for supporting children with medical complexity.[13] The study frames such tools as ways to enhance communication, information exchange, medical safety and care coordination.[13] Leaders should budget for nurse coordinators, schedulers who can build multispecialty days and data managers who maintain registries, because these roles keep the route intact between visits.

Remote models change workforce needs rather than removing them. In the Ukrainian experience, a short initial treatment period of 2 to 4 weeks was used to assess response under remote medical supervision.[5] Models like that depend on clinicians who review progress at a distance, staff who manage family messages and clear rules for when a child must be seen in person. Leaders should plan those roles explicitly instead of absorbing them into already full clinic schedules.

Executive guidance · Operating dashboard

Measure whether the operating route works as intended.

Do not publish a number until the organization defines its numerator, denominator where relevant, owner, source system, exclusions, review cadence, and limits. The candidates below are management prompts, not benchmarks or reported results.

Four operating signals

Entry-point clarityOwnership reliabilitySpecialty-route clarityImprovement closure

Each signal pairs an executive question with one candidate local measure, set out below.

Executive guidance · Signal

Entry-point clarity

Can people and staff identify the approved first step without searching across conflicting instructions?

Candidate local measure
Locally defined contact, routing, and repeat-contact signals by channel and service.

Executive guidance · Signal

Ownership reliability

Does a specific team accept each request and make its status visible?

Candidate local measure
Requests without an owner, aged work, transfers, and escalations using locally approved definitions.

Executive guidance · Signal

Specialty-route clarity

Can frontline and access teams identify the appropriate receiving resource without relying on personal memory?

Candidate local measure
Locally defined misroutes, searches, returned work, unresolved referrals, escalation, and navigation feedback.

Executive guidance · Signal

Improvement closure

Does the organization correct recurring friction and report what changed?

Candidate local measure
Selected barriers, assigned actions, completion status, and post-change review.

Figure 4

The operating system behind the dashboard

The operating system behind the dashboardThe four operating signals from this brief’s dashboard, each tied to the candidate owner named in the executive scorecard, around one accountable route. Drawn from the page’s original executive guidance.Accountableoperating route(executive sponsor)Entry-point clarityOwner: Executive sponsor andoperational leadOwnership reliabilityOwner: Operational owner andparticipating teamsSpecialty-route clarityOwner: Sending and receiving ownersImprovement closureOwner: Improvement owner andexecutive sponsor

The four operating signals from this brief’s dashboard, each tied to the candidate owner named in the executive scorecard, around one accountable route. Drawn from the page’s original executive guidance.

Data note. Structural diagram; no measured values.

Limitation. Owners are candidates to be confirmed locally.

Figure data (4 rows)
Figure 4 data: The operating system behind the dashboard
Operating signalCandidate owner
Entry-point clarityExecutive sponsor and operational lead
Ownership reliabilityOperational owner and participating teams
Specialty-route claritySending and receiving owners
Improvement closureImprovement owner and executive sponsor

Executive guidance · Handoff workflow

Keep work owned when it crosses a boundary.

A handoff is reliable only when the sending party knows who is expected to receive the work, the receiving party acknowledges responsibility, and any unresolved exception remains visible. Local policy and qualified judgment control the actual process.

How responsibility moves

Lane AFrom message to accepted ownership4 steps
Lane BFrom accepted ownership to verified follow-through4 steps

Lane A

From message to accepted ownership

  1. Confirm the approved message and intended audience.
  2. Publish the actual entry point and receiving role.
  3. Acknowledge receipt using the locally approved method.
  4. Escalate when ownership or response remains unclear.

Lane B

From accepted ownership to verified follow-through

  1. Record the next accountable owner and visible status.
  2. Identify the designated receiving resource and keep the request visible when the appropriate owner is not immediately available.
  3. Keep unresolved work visible across boundaries.
  4. Confirm closure or document the continuing exception.

Executive guidance · Executive scorecard

Ask questions that connect intent, ownership, and results.

The scorecard keeps review focused on decisions. Leaders should set definitions locally, examine variation without overclaiming cause, and pair quantitative signals with the experience of people who use and operate the route.

Who reviews what

  • Executive sponsor and operational lead
  • Operational owner and participating teams
  • Sending and receiving owners
  • Improvement owner and executive sponsor

Candidate owners named in the scorecard, confirmed locally.

Candidate questions and ownership assignments. These are not external benchmarks.
Operating signalExecutive questionCandidate ownerSuggested review point
Entry-point clarityCan people and staff identify the approved first step without searching across conflicting instructions?Executive sponsor and operational leadAt campaign launch and close
Ownership reliabilityDoes a specific team accept each request and make its status visible?Operational owner and participating teamsAt a locally defined cadence
Specialty-route clarityCan frontline and access teams identify the appropriate receiving resource without relying on personal memory?Sending and receiving ownersAt a locally defined cadence
Improvement closureDoes the organization correct recurring friction and report what changed?Improvement owner and executive sponsorUntil action is verified

Figure 5

Control points for a reliable vascular anomalies pathway

Figure 5: Control points for a reliable vascular anomalies pathway
Control pointRisk if missingOwnerEvidence of control
Single referral entry point to multidisciplinary reviewComplex cases bounce between specialists before anyone owns the planVascular anomalies program directorDays from referral to first joint review
Genetic testing with tissue-based analysis when indicatedOverlapping phenotypes are misclassified and targeted therapy is delayedMedical genetics lead with laboratory directorShare of eligible patients with completed testing and results reviewed
Targeted therapy access and monitoring ownerApproved therapies stall at authorization, dispensing or safety monitoringSpecialty pharmacy manager and treating physician leadTime from decision to first dose and monitoring completion
Coordinated single-day visits and remote follow-upFamilies make repeated trips and miss follow-upAmbulatory operations leaderTrips per family before a plan is set; remote follow-up use
Cross-specialty follow-up trackingSystemic findings such as cardiac enlargement go without planned reviewProgram nurse coordinatorShare of flagged patients with completed follow-up studies
Planned transition to adult servicesAdolescents lose history, imaging and treatment records at transferPediatric and adult program leadsShare of transition-age patients with a documented handoff and first adult visit
Family-reported outcome measurementPain and function burden stays invisible to governanceQuality director and board quality committeeCollection rate and review of pain and physical function measures

Control points derived from the cited evidence [1], [3], [4], [5], [11], [12], [13] and this brief’s executive guidance.

Data note. Each row is a control to verify, not a measured result.

Limitation. Owners and evidence of control must follow local policy and applicable requirements.

Public communication

Public communication, measurement and governance

Awareness messages should point families to a working route, not only to information. Family-reported outcomes give that route a measure that matters to the people using it. The overgrowth spectrum study collected quantitative survey data for up to 12 months and added qualitative interviews with a subset of participants.[3] That mixed design captured pain, physical functioning and daily activities in the words of patients and caregivers.[3]

Measurement also depends on data that can move between systems. A French implementation study built an auditable pipeline to transfer national rare disease registry records into a specialty research data warehouse.[6] Tested on an export of 1000 real patients, it created 641 patient profiles with a 99% success rate for attempted imports.[6] Directly mapped and inferred variables showed full concordance (100%), and the tool later processed up to 5000 patient records.[6] Vascular anomaly programs that want to report outcomes need similarly explicit data rules.

Governance frameworks for rare disease pathways now exist. The European consensus study predefined agreement using three thresholds.[2] These were a median score of at least 4, an interquartile range of 1 or less and at least 80% of ratings at 4 or 5.[2] Its seven themes give boards a usable checklist, from national strategy and governance to patient empowerment.[2] Leaders can map their vascular anomalies program against each theme and name an owner for every gap they find.

Public communication should be honest about the limits of the evidence. Much of the published experience comes from retrospective, single-center series, such as the committee review and the hand malformation cohort.[1][12] Treatment experience reports are also small, with 14 participants on therapy in the overgrowth spectrum study.[3] Messages for CLOVES Syndrome Awareness Day can name a clear entry point and explain how multidisciplinary review works. They can also report what the organization is measuring, without promising outcomes the evidence cannot support.

Clinician-facing communication matters as much as public messaging. The survey authors call for vascular anomalies in the residency curriculum and more interdisciplinary clinics in training programs.[14] Short referral guides, case conferences and a named consult contact can make the route visible to primary care, emergency and surgical teams. Each awareness campaign is also a chance to ask families how they found the program and how long it took, then publish what the organization changed in response.

A girl splashes with her younger brother in a small backyard pool while their mother sits nearby.
Illustrative image. Community caregivers named transition to adult care as a main theme in caring for children with medical complexity.[13]

Executive guidance · 90-day plan

Move from listening to a verified improvement in 90 days.

The time boxes below are a management framework, not a clinical timeline. Adjust them to risk, scope, governance, resources, stakeholder participation, and applicable review requirements.

Ninety days, three moves

  1. Days 1–30See the current route
  2. Days 31–60Build the reliable path
  3. Days 61–90Make the change visible

Days 1–30 · Listen and map

See the current route

  • Name an executive sponsor and an operational owner.
  • Listen to people using the route and representative frontline teams.
  • Map how CLOVES Syndrome Awareness Day communications connect to real entry points, owners, transitions, and escalation.
  • Select one recurring barrier that the organization can responsibly address.

Days 31–60 · Design and test

Build the reliable path

  • Define the trigger, receiving owner, required information, acknowledgment, escalation, and closure signal.
  • Validate the design with every sending and receiving team involved.
  • Document and test one specialty-navigation route so it does not depend on informal knowledge alone.
  • Test the route in more than one representative setting or operating period where practical.

Days 61–90 · Implement and verify

Make the change visible

  • Launch the redesigned route with a small set of locally defined measures.
  • Review unresolved work and recurring friction using a learning approach.
  • Correct implementation barriers and record who owns each remaining dependency.
  • Report what changed, what evidence was reviewed, and what still requires live oversight.

Figure 6

The 90-day plan on one timeline

The 90-day plan on one timelineThe 90-day plan from this brief drawn as a timeline: each action sits in the 30-day window the plan assigns it. The full wording of each action is in the figure data and in the plan above.Day 0Day 30Day 60Day 90Name an executive sponsor and an operational owner.Days 1–30: Name an executive sponsor and an operational owner.Listen to people using the route and representative frontlineteams.Days 1–30: Listen to people using the route and representative frontline teams.Map how CLOVES Syndrome Awareness Day communications connectto real entry points, owners, transitions, and escalation.Days 1–30: Map how CLOVES Syndrome Awareness Day communications connect to real entry points, owners, transitions, and escalation.Select one recurring barrier that the organization canresponsibly address.Days 1–30: Select one recurring barrier that the organization can responsibly address.Define the trigger, receiving owner, required information,acknowledgment, escalation, and closure signal.Days 31–60: Define the trigger, receiving owner, required information, acknowledgment, escalation, and closure signal.Validate the design with every sending and receiving teaminvolved.Days 31–60: Validate the design with every sending and receiving team involved.Document and test one specialty-navigation route so it doesnot depend on informal knowledge alone.Days 31–60: Document and test one specialty-navigation route so it does not depend on informal knowledge alone.Test the route in more than one representative setting oroperating period where practical.Days 31–60: Test the route in more than one representative setting or operating period where practical.Launch the redesigned route with a small set of locallydefined measures.Days 61–90: Launch the redesigned route with a small set of locally defined measures.Review unresolved work and recurring friction using a learningapproach.Days 61–90: Review unresolved work and recurring friction using a learning approach.Correct implementation barriers and record who owns eachremaining dependency.Days 61–90: Correct implementation barriers and record who owns each remaining dependency.Report what changed, what evidence was reviewed, and whatstill requires live oversight.Days 61–90: Report what changed, what evidence was reviewed, and what still requires live oversight.Listen and mapDesign and testImplement and verify

The 90-day plan from this brief drawn as a timeline: each action sits in the 30-day window the plan assigns it. The full wording of each action is in the figure data and in the plan above.

Data note. Time boxes are a management framework, not a clinical timeline.

Limitation. Durations are uniform 30-day windows; real tasks may span windows.

Figure data (12 rows)
Figure 6 data: The 90-day plan on one timeline
WindowAction
Days 1–30 · Listen and mapName an executive sponsor and an operational owner.
Days 1–30 · Listen and mapListen to people using the route and representative frontline teams.
Days 1–30 · Listen and mapMap how CLOVES Syndrome Awareness Day communications connect to real entry points, owners, transitions, and escalation.
Days 1–30 · Listen and mapSelect one recurring barrier that the organization can responsibly address.
Days 31–60 · Design and testDefine the trigger, receiving owner, required information, acknowledgment, escalation, and closure signal.
Days 31–60 · Design and testValidate the design with every sending and receiving team involved.
Days 31–60 · Design and testDocument and test one specialty-navigation route so it does not depend on informal knowledge alone.
Days 31–60 · Design and testTest the route in more than one representative setting or operating period where practical.
Days 61–90 · Implement and verifyLaunch the redesigned route with a small set of locally defined measures.
Days 61–90 · Implement and verifyReview unresolved work and recurring friction using a learning approach.
Days 61–90 · Implement and verifyCorrect implementation barriers and record who owns each remaining dependency.
Days 61–90 · Implement and verifyReport what changed, what evidence was reviewed, and what still requires live oversight.

Executive guidance · Leadership close

Carry one accountable improvement beyond the campaign window.

Recognition matters. It becomes durable when leaders also listen, clarify the route, support the people operating it, close an identified gap, and report the result without claiming more than the evidence supports.

Leadership commitment

Listen to the people closest to the route, assign one barrier, and verify the change.

Executive action kit · Day observance

Turn CLOVES Syndrome Awareness Day into accountable action.

Use the observance to review how people find information, enter the right route, and remain connected through follow-through.

Take it with you

Filed under

Chronic Disease and Specialty CarePublic Health and PreventionDay

Leadership focus

Use this observance to examine navigation, longitudinal ownership, and specialty-care coordination. Select one verified barrier, assign an accountable owner, and carry the improvement beyond the campaign window.

Workforce lens

Ask whether staffing, role clarity, training, tools, workload, and escalation support the people operating the information, specialty navigation, coordination, and continuing support pathway.

Patient and community lens

Make the approved first step clear. Test whether a person can move from information to an acknowledged next action without navigating conflicting instructions.

Equity and access lens

Review distance, coverage, language, disability, digital access, and the burden placed on people and families to coordinate complex routes themselves.

Five-minute briefing

Inspect the operating sequence

Listen with people and families using the pathway, primary care, specialty services, navigation teams, and support organizations. Find one unclear referral ownership, fragmented information, or a connection that is not completed, then test the locally approved route from entry through acknowledged follow-through.

  1. Listen
  2. Clarify entry
  3. Navigate specialty boundaries
  4. Protect transitions
  5. Verify and learn
Leadership actions for this week
  • Name an executive sponsor and frontline operating owner.
  • Ask people using and operating the pathway where ownership becomes unclear.
  • Test one representative route from first question to acknowledged next step.
  • Select one barrier that can be corrected without overstating the evidence.
  • Set a review date and define how completion will be verified.
Candidate measures

Define every numerator, denominator where relevant, owner, data source, exclusions, cadence, and limitation locally. These are management prompts, not external benchmarks.

  • Locally defined contact, routing, and repeat-contact signals by channel and service.
  • Requests without an owner, aged work, transfers, and escalations using locally approved definitions.
  • Locally defined misroutes, searches, returned work, unresolved referrals, escalation, and navigation feedback.
Department readiness checklist
  • The public and staff entry points match the actual approved process.
  • A specific role accepts each request, referral, or escalation.
  • Handoffs include acknowledgment and a visible unresolved state.
  • Language, disability, digital, transportation, and trust barriers receive explicit review.
  • Communications do not introduce unsupported themes, statistics, or clinical advice.
  • A named leader will review what changed after the observance.
Intended audiences
  • Executive and Operational Leaders
  • Patient Experience and Access Leaders
Staff communication template

During CLOVES Syndrome Awareness Day, our organization will connect awareness with a practical review of the information, specialty navigation, coordination, and continuing support pathway. Use approved information, identify the correct entry point, confirm ownership when work moves, protect privacy, and escalate unresolved barriers through local channels.

Community communication template

CLOVES Syndrome Awareness Day is an opportunity to share trustworthy information and make the next step easier to find. Use our approved channels for information and support. If a request changes hands, our goal is to keep ownership and follow-through visible.

Measurement worksheet
Signal
What observable condition will show whether the route works?
Definition
What is included, excluded, and counted?
Owner
Who reviews the signal and acts on exceptions?
Cadence
When will leaders review it?
Equity check
Which differences require protected, locally appropriate review?
Closure
What evidence will confirm the improvement was completed?
Editorial review
Completed
Source records
2 listed under Authoritative resources
Review standard
Sourced facts remain separated from original executive guidance
Clinical boundary
No new statistical or clinical claim was added by this action kit

Sources and content boundary

Authoritative resources

Use note: All operating models, measures, scorecard questions, and action steps are original executive guidance. This article supports leadership planning and education. It does not replace clinical judgment, emergency procedures, legal advice, professional standards, organizational policy, or applicable federal, state, and local requirements.

Peer-reviewed references

References

Fifteen peer-reviewed sources, newest first. Each was individually verified through authenticated academic research databases. Bracketed numbers in the text link here; the original executive guidance on this page carries no citations because it is guidance, not a sourced claim. Sources last checked in those databases on .

  1. 1. Role of a Multidisciplinary Vascular Anomalies Committee in the Management of Pediatric Patients: A Decade-Long Experience. Annals of Vascular Surgery. 2026;124:339-345. https://doi.org/10.1016/j.avsg.2025.11.130
  2. 2. Developing consensus on rare disease care pathways and ERN integration across Europe: insights from stakeholder workshops and a Delphi study. European Journal of Medical Genetics. 2026;83:105096. https://doi.org/10.1016/j.ejmg.2026.105096
  3. 3. Health‐Related Quality of Life and Symptom Severity Among Patients With PIK3CA ‐Related Overgrowth Spectrum: A Mixed‐Methods Study to Understand Real‐World Experience With Alpelisib Treatment. Pediatric Blood & Cancer. 2026;73(8):e70368. https://doi.org/10.1002/1545-5017.70368
  4. 4. Clinical and molecular characterization of non-PIK3CA-related vascular malformations with overgrowth in a pediatric cohort. World Journal of Pediatrics. 2026;22(9):1024-1039. https://doi.org/10.1007/s12519-026-01098-3
  5. 5. Topical Timolol Beyond Infancy: A Retrospective Study of Its Use in Persistent Infantile Hemangiomas. Dermatology and Therapy. 2026;16(7):3295-3306. https://doi.org/10.1007/s13555-026-01782-2
  6. 6. Interoperable Integration of a National Rare Disease Registry Into a Rare Eye Disease Data Warehouse: Implementation Study. JMIR Medical Informatics. 2026;14:e79378-e79378. https://doi.org/10.2196/79378
  7. 7. Medical Therapies for Vascular Anomalies: What Interventional Radiologists Need to Know. Journal of Vascular and Interventional Radiology. 2026;37(10):108928. https://doi.org/10.1016/j.jvir.2026.108928
  8. 8. Bleomycin Electrosclerotherapy and Skin Hyperpigmentation in Slow-flow Vascular Malformations: A Retrospective Monocentric Analysis. RöFo - Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren. 2026;198(10):1302-1309. https://doi.org/10.1055/a-2783-4420
  9. 9. Arteriolymphatic Malformation in KRAS-related Parkes Weber Syndrome of Lower Limbs. Academic Radiology. 2026. https://doi.org/10.1016/j.acra.2026.07.075
  10. 10. Prise en charge des malformations veineuses : étude prospective de 33 cas. Annales de Chirurgie Plastique Esthétique. 2026;71(2):140-149. https://doi.org/10.1016/j.anplas.2025.09.008
  11. 11. Factors influencing cardiomegaly and cardiac size changes after endovascular treatment in peripheral arteriovenous malformations. Acta Radiologica. 2025;67(2):208-216. https://doi.org/10.1177/02841851251405785
  12. 12. Multidisciplinary approach to hand arteriovenous malformations: Treatment strategies and clinical outcomes - insights from a 25-year experience at a single vascular anomalies center. Journal of Vascular Surgery: Venous and Lymphatic Disorders. 2025;13(1):101964. https://doi.org/10.1016/j.jvsv.2024.101964
  13. 13. Community Caregivers’ Perspectives on Health IT Use for Children With Medical Complexity: Qualitative Interview Study. JMIR Pediatrics and Parenting. 2025;8:e67289. https://doi.org/10.2196/67289
  14. 14. Are We Overlooking Vascular Anomalies in Oral and Maxillofacial Surgical Training?. Journal of Maxillofacial and Oral Surgery. 2024;24(1):30-35. https://doi.org/10.1007/s12663-024-02401-3
  15. 15. Lymphatic Malformations in Parkes Weber’s Syndrome: Retrospective Review of 16 Cases in a Vascular Anomalies Center. European Journal of Pediatric Surgery. 2023;34(01):078-083. https://doi.org/10.1055/a-2156-5000

Claim-to-source matrix

What each source supports

Every sourced claim in the new sections maps to the references that support it, the section where it is used, and the limitation a reader should keep in mind. Original executive guidance carries no sources because it is guidance, not a finding.

Claim-to-source matrix
Claim groupSourcesYearsUsed inLimitation
Multidisciplinary committee review and pediatric outcomes[1]2026Current evidenceRetrospective descriptive single-committee study without a comparison group.
Genetic heterogeneity and functional burden in vascular malformations with overgrowth[4] [9] [15]2026, 2023Current evidenceSmall retrospective cohorts from tertiary centers; genotype findings may not generalize.
Systemic and long-term burden of arteriovenous malformations[11] [12]2025Current evidenceSingle-center retrospective reviews spanning decades of changing practice.
Lifelong course and need for longitudinal care and medical therapy[3] [7] [10]2026Continuum of careNarrative review and small case series; outcome data for medical therapies remain limited.
Patient and caregiver experience with the overgrowth spectrum and targeted therapy[3]2026AccessObservational study of 77 participants, only 14 on treatment at enrollment; recruitment partly via advocacy organizations.
Remote supervision to sustain access during disruption[5]2026AccessSingle-center real-world study of infantile hemangioma, not CLOVES; no randomized comparison.
Caregiver roles, transition to adult care and health IT needs[13]2025Continuum of careTwelve qualitative interviews from one advocacy network on the U.S. East Coast.
Workforce exposure and training gaps[14]2024Human infrastructureSurvey with a 15.5% response rate in one specialty.
Procedural risk communication[8]2026Human infrastructureRetrospective single-center analysis over 21 months.
Rare disease pathway governance, equity and data interoperability[2] [6]2026Public communicationEuropean consensus and French implementation settings; transfer to U.S. systems is untested.
Greg Wahlstrom in his office at The Healthcare Executive

About the author

Greg Wahlstrom

MBAHCM

President and Chief Executive Officer, The Healthcare Executive

©2014 – 2026 The Healthcare Executive. All rights reserved.

Back to the contents

Health Observance Calendar

See next month’s observances before it starts.

One email ahead of each month with the health observances coming up and the executive briefs that go with them.

Sent by The Healthcare Executive. Unsubscribe at any time. See our Privacy Policy.